| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | 20.854 | 25.434 | 26.539 | 25.631 | 30.023 | 26.237 | 28.023 | 30.733 | 25.301 | 29.693 |
| Total Income - EUR | 20.857 | 25.472 | 26.539 | 25.631 | 30.023 | 26.262 | 28.049 | 30.748 | 25.301 | 29.693 |
| Total Expenses - EUR | 18.107 | 20.357 | 22.070 | 21.882 | 27.379 | 23.253 | 24.301 | 27.224 | 25.909 | 29.209 |
| Gross Profit/Loss - EUR | 2.750 | 5.115 | 4.470 | 3.749 | 2.644 | 3.008 | 3.748 | 3.524 | -609 | 484 |
| Net Profit/Loss - EUR | 2.125 | 4.761 | 4.205 | 3.495 | 2.343 | 2.764 | 3.468 | 3.223 | -862 | 407 |
| Employees | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
Check the financial reports for the company - Noroptic S.r.l.
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Current Assets | 4.288 | 6.344 | 6.024 | 5.672 | 6.267 | 6.325 | 7.794 | 7.742 | 7.316 | 8.121 |
| Inventories | 3.296 | 2.932 | 3.778 | 4.467 | 5.718 | 5.314 | 6.981 | 6.477 | 6.934 | 7.394 |
| Receivables | 491 | 2.585 | 1.861 | 699 | 366 | 359 | 351 | 353 | 351 | 630 |
| Cash | 501 | 827 | 385 | 506 | 183 | 652 | 461 | 913 | 31 | 97 |
| Shareholders Funds | 2.179 | 4.814 | 4.257 | 3.546 | 2.394 | 2.814 | 3.516 | 3.271 | -813 | -402 |
| Social Capital | 45 | 45 | 44 | 43 | 42 | 41 | 40 | 41 | 40 | 40 |
| Debts | 2.109 | 1.530 | 1.767 | 2.126 | 3.873 | 3.511 | 4.277 | 4.471 | 8.129 | 8.523 |
| Income in Advance | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "4778 - 4778" | |||||||||
| CAEN Financial Year |
4774
|
|||||||||
Comments - Noroptic S.r.l.